WO2016005897A1 - Combination of pregabalin and meloxicam for the treatment of neuropathic pain - Google Patents
Combination of pregabalin and meloxicam for the treatment of neuropathic pain Download PDFInfo
- Publication number
- WO2016005897A1 WO2016005897A1 PCT/IB2015/055127 IB2015055127W WO2016005897A1 WO 2016005897 A1 WO2016005897 A1 WO 2016005897A1 IB 2015055127 W IB2015055127 W IB 2015055127W WO 2016005897 A1 WO2016005897 A1 WO 2016005897A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination
- meloxicam
- effects
- pregabalin
- pgb
- Prior art date
Links
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 title claims abstract description 144
- 229960001929 meloxicam Drugs 0.000 title claims abstract description 139
- 229960001233 pregabalin Drugs 0.000 title claims abstract description 113
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 113
- 238000011282 treatment Methods 0.000 title claims abstract description 110
- 208000004296 neuralgia Diseases 0.000 title claims description 85
- 208000021722 neuropathic pain Diseases 0.000 title claims description 85
- 208000002193 Pain Diseases 0.000 claims abstract description 52
- 230000036407 pain Effects 0.000 claims abstract description 50
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 230000002195 synergetic effect Effects 0.000 claims abstract description 14
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 41
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 21
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 14
- 239000003981 vehicle Substances 0.000 claims description 14
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000011885 synergistic combination Substances 0.000 claims description 9
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 8
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 8
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 208000007514 Herpes zoster Diseases 0.000 claims description 7
- -1 lyophilized Substances 0.000 claims description 7
- 201000001119 neuropathy Diseases 0.000 claims description 7
- 230000007823 neuropathy Effects 0.000 claims description 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 7
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 7
- 238000002266 amputation Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 230000003637 steroidlike Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003979 granulating agent Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 230000003070 anti-hyperalgesia Effects 0.000 abstract description 107
- 230000003574 anti-allodynic effect Effects 0.000 abstract description 60
- 230000002981 neuropathic effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 description 164
- 241000700159 Rattus Species 0.000 description 86
- 230000001684 chronic effect Effects 0.000 description 81
- 208000004454 Hyperalgesia Diseases 0.000 description 71
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 66
- 231100000673 dose–response relationship Toxicity 0.000 description 43
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 36
- 230000001154 acute effect Effects 0.000 description 36
- 206010053552 allodynia Diseases 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 35
- 238000012360 testing method Methods 0.000 description 35
- 208000035154 Hyperesthesia Diseases 0.000 description 30
- 230000006378 damage Effects 0.000 description 30
- 208000014674 injury Diseases 0.000 description 30
- 208000027418 Wounds and injury Diseases 0.000 description 28
- 230000004044 response Effects 0.000 description 22
- 230000003993 interaction Effects 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 19
- 229960002870 gabapentin Drugs 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 13
- 229930195725 Mannitol Natural products 0.000 description 13
- 239000000594 mannitol Substances 0.000 description 13
- 235000010355 mannitol Nutrition 0.000 description 13
- 229960001855 mannitol Drugs 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 210000003497 sciatic nerve Anatomy 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 11
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 10
- 229960002009 naproxen Drugs 0.000 description 10
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 10
- 230000000144 pharmacologic effect Effects 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 229920002261 Corn starch Polymers 0.000 description 8
- 239000008120 corn starch Substances 0.000 description 8
- 229940099112 cornstarch Drugs 0.000 description 8
- 229960001375 lactose Drugs 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 229940057948 magnesium stearate Drugs 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000003502 anti-nociceptive effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000003040 nociceptive effect Effects 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 229960001777 castor oil Drugs 0.000 description 5
- 229940097362 cyclodextrins Drugs 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 229960000502 poloxamer Drugs 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 229950008882 polysorbate Drugs 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 229940071138 stearyl fumarate Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 229940033134 talc Drugs 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229940091250 magnesium supplement Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 2
- 229940124596 AChE inhibitor Drugs 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229940105781 meloxicam 10 mg Drugs 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229960001816 oxcarbazepine Drugs 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000010490 psychological well-being Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010017815 Gastric perforation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 201000003129 Kidney Papillary Necrosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 1
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- MTCMTKNMZCPKLX-UHFFFAOYSA-N chembl359570 Chemical compound N=1OC=2C=C3NC(=O)CC3=CC=2C=1CCC(CC1)CCN1CC1=CC=CC=C1 MTCMTKNMZCPKLX-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940038665 combination meloxicam Drugs 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- TZDUHAJSIBHXDL-UHFFFAOYSA-N gabapentin enacarbil Chemical compound CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 TZDUHAJSIBHXDL-UHFFFAOYSA-N 0.000 description 1
- 229960002359 gabapentin enacarbil Drugs 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229950010480 icopezil Drugs 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000014987 limb edema Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960004143 tapentadol hydrochloride Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940124279 traditional non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- RNWHGQJWIACOKP-UHFFFAOYSA-N zinc;oxygen(2-) Chemical class [O-2].[Zn+2] RNWHGQJWIACOKP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Definitions
- the present invention refers to the pharmacological combination of an antihyperalgesic, antiallodynic, and anti ⁇ inflammatory agent, as well as pharmaceutical compositions comprising such a combination, as well as the use thereof for prevention and/or treatment of pain caused by different neuropathic etiologies.
- the present invention describes a combination of a ⁇ -aminobutyric acid (GABA) analogue agent and non-steroidal anti-inflammatory agent (NSAID) revealing a synergistic effect, pharmaceutical compositions comprising it and the use of this combination and pharmaceutical compositions to treat and/or prevent neuropathic pain caused by diabetic neuropathy, neuropathy after appearance of herpes zoster, neuralgia of trigeminal nerve, HIV, pain of the phantom member after an amputation, neuropathic pain of lumbar and dorsal region.
- GABA ⁇ -aminobutyric acid
- NSAID non-steroidal anti-inflammatory agent
- nociceptive transient pain in response to a noxious stimulus
- inflammatory sustained pain in response to inflammation and tissue damage
- neuropathic spontaneous pain and pain hypersensitivity in association with nervous system damage or injury
- psychogenic the pain is only in patient's mind, without any organic cause that justifies it
- functional no injury, pain hypersensitivity that results from an alteration of abnormal visceral processing or function
- Neuropathic pain is a chronic condition caused by nervous system injury. Unlike the protective acute pain, neuropathic pain persists and does not have a useful purpose severely affecting patient's quality of life (Shah et al, 2003) . Neuropathic pain is a consequence of various types of pathological processes affecting central or peripheral nervous system neurons (Zhuo, 2007) . This type of pain is part of a wide range of conditions such as trauma, diabetes mellitus, herpes zoster, cancer, HIV, etc.
- Neuropathic pain includes spontaneous stimulus-dependent and stimulus-independent pain characterized by hyperalgesia and allodynia (Zhuo, 2007) . Many patients who experience nerve damage do not develop neuropathic pain. However, those who develop it suffer severe abnormal pain and long-lasting syndromes after central or peripheral neural damage.
- neuropathic pain has become the cornerstone and the primary objective of hospital units and/or pain clinical units. This happens not only because of its frequency, but essentially by its resistance to common analgesic treatments and to a broad lack of knowledge about the pathology administration that cause it, inducing to resort periodically to pain treatment specialists .
- Treatments currently used in hospital units and/or pain clinical units for control of these patients are varied, using drugs that by their action mechanism are capable of decreasing nervous system excitability, severely damaged by the manifested disease process.
- neuromodulators are grouped under the name of neuromodulators and can act under two different capacities: a) decreasing pathological mechanisms that extend or trigger pain impulses, or b) enhancing the mechanisms that inhibit painful transmission or perception; in conclusion, negatively or positively modulating a neural activity.
- neuropathic pain in recent years has moved from being a simple control method of symptoms to an improved and comprehensive care of several different characteristics involved in a painful sensation, based on a better understanding of those mechanisms which cause and maintain the pain.
- a number of drugs belonging to the families of analgesics, non-steroidal anti-inflammatory, norepinephrine inhibitors, opioids and others have been used in neuropathic pain treatment basic care. Although these treatments are nowadays considered clinically significant in only fifty percent of the cases, the use of another type of antidepressant drugs and anticonvulsants, such as adjuvants for managing this type of pain, has been a choice, with relative success due to their high side effect incidence.
- One of the first choice treatments consists of administering the drug gabapentin, which demonstrates multiple side effects such as drowsiness, weakness or tiredness, dizziness, headache, uncontrollable tremor in any part of the body, double or blurred vision, instability, anxiety, nausea, vomiting, heartburn, diarrhea, dry mouth, constipation, increased appetite.
- the present invention provides new pharmacological proposals, such as pharmaceutical compositions comprising a synergistic combination of an ant ihyperalgesic, ant iallodynic agent and an anti-inflammatory non-steroidal agent, manifesting minor side effects due to a decrease of administered daily doses of these agents with respect to those recommended when those are individually prescribed.
- a preferred embodiment of antihyperalgesic, antiallodynic agent of the present invention is pregabalin, a gamma-aminobutyric acid (GABA) structural analogue, the main neurotransmitter with central nervous system (CNS) inhibitory function. Structurally, it is a chemical modification of GABA, the ( S ) -3-i sobutylgaba .
- GABA gamma-aminobutyric acid
- CNS central nervous system
- the mechanism of action whereby its pharmacological activity is developed is based on its ability to link to the alpha-2-delta subunit ( ⁇ 2 ⁇ ) , protein fraction associated to voltage-dependent calcium channels in the CNS.
- ⁇ 2 ⁇ alpha-2-delta subunit
- a reduction of calcium entry into the presynaptic nerve endings is produced by modulating these channels, with a decrease in releasing several excitatory neurotransmitters, including glutamate, noradrenaline, CGRP and substance P at the spinal cord level, this being the suggested mechanism to explain this drug analgesic, antiepilept ic, and anxiolytic properties.
- Pregabalin is more cost-effective than Gabapentin in treatment of patients with post-herpetic neuropathy and diabetic neuropathy.
- the improvement includes a reduction of pain measured by different scales, improvement of sleep disorder and improvement in some domains of quality of life scales, in the mood and perception of the patient about a successful evolution compared to pre-treatment status.
- pregabalin improved pain, sleep, anxiety and quality of life scales in patients with central pain due to spinal cord injury and patients with multiple cause central pain: hemispheric, backbone, trunk, or ischemic injury.
- Another preferred embodiment of present invention is Meloxicam, as non-steroidal anti-inflammatory agent, which inhibits prostaglandin biosynthesis more intensively on the inflammation site in the gastric mucosa or in kidney, and it has been postulated that such action may be related to the selective inhibition of COX-2 over COX-1 a characteristic absent in non-selective NSAIDs.
- Meloxicam is an enolic acid derivative, having a good gastrointestinal and renal tolerance profile. Compared to the traditional non-steroidal anti-inflammatory drugs, Meloxicam does not inhibit platelet aggregation induced by arachidonic acid or collagen but significantly reduces thromboxane platelet production.
- Meloxicam is orally administered, but it may be also intramuscularly or rectally administered. After oral administration, its absorption is slow reaching higher plasma concentrations at 4-5 hours. Absolute bioavailability is 90%. The drug experiences gastrointestinal recirculation, since a second maximum concentration peak is observed at 12-14 hours. Drug absorption is not affected by the presence of food, but increases 22% maximum plasma concentrations. The drug extensively joins to plasma proteins (99%) particularly albumin. Meloxicam is extensively metabolized by CYP2C9 (with a lower contribution from CYP3A4) enzyme system, producing 4 inactive metabolites. 43% of administered dose is urine excreted, primarily in the form of metabolites, while the rest is excreted in feces.
- Meloxicam exhibits a linear pharmacokinetic profile, with 15 to 20 hour elimination half- life. Equilibrium state is reached after five doses (one per day) . Women show lower plasma concentrations of Meloxicam than men of the same age. In an equilibrium situation, elimination half-life is 17.9 hours for women and 21.4 hours for men. However, maximum concentrations are similar for both sexes .
- Meloxicam is prescribed as an analgesic to relieve mild to moderate pain, as well as for treatment of osteoarthritis, acute and chronic rheumatoid arthritis, shoulder and hip periarthritis, muscle strain and gout attack signs and symptoms, and for treatment of ankylosing spondylitis symptoms. It is also useful for treatment of inflammation secondary to trauma, as well as soft tissue inflammatory processes (airways), gynecological diseases and primary dysmenorrhoea .
- Meloxicam has demonstrated safety and efficacy in pain and stiffness management in patients with osteoarthritis, with better gastrointestinal tolerability than other NSAIDs such as diclofenac and Piroxicam, and same tolerability than placebo, favoring a better adherence to treatment. Incidence of digestive side reactions is lower with Meloxicam than that observed with other NSAIDs such as Piroxicam, diclofenac, or naproxen; however, the following side reactions have been described with its use: abdominal pain, diarrhea, dyspepsia, flatulence, nausea, vomiting, dizziness, flu-like symptoms, sore throat, upper respiratory tract infections, anemia, alopecia, rash, pruritus, photosensitizing agents, increased sweating and urticaria.
- the object of present invention is to provide a synergistic combination of pregabalin or pharmaceutically acceptable salts thereof and Meloxicam or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising such combination in the same dosage unit, which manifest minor side effects due to a decrease of administered daily doses of these drugs with respect to the recommended when they are prescribed separately, and the use of these for prevention and/or treatment of neuropathic pain caused by several etiologies, such as diabetic neuropathy, neuropathy after herpes zoster appearance, trigeminal nerve neuralgia, HIV, pain of the phantom member after an amputation, neuropathic pain of lumbar and dorsal region.
- neuropathic pain caused by several etiologies, such as diabetic neuropathy, neuropathy after herpes zoster appearance, trigeminal nerve neuralgia, HIV, pain of the phantom member after an amputation, neuropathic pain of lumbar and dorsal region.
- MX 237693 B patent document refers to combinations of at least one antiepileptic compound and at least one selected compound of the group consisting of analgesics, NSAIDs and antagonists of NMDA receptor, for pain relief.
- Such patent specifically claims combinations of Gabapentin with naproxen and pregabalin with naproxen. This document neither describes nor suggests any antiallodynic, antihyperalgesic and anti- inflammatory synergistic effect with a combination of pregabalin and Meloxicam.
- MX 288732 B patent document claimed a pharmaceutical composition composed of active ingredients, Gabapentin and Meloxicam formulated in the same oral pharmaceutical forms.
- Mexican patent MX 252662 B refers to a combination characterized by comprising a synergistic relationship of an alpha-2-delta ligand and a PDEV inhibitor, used for the preparation of a useful drug in curative, prophylactic or palliative treatment of pain, particularly neuropathic pain.
- Alpha-2-delta ligand is particularly selected from Gabapentin and pregabalin and PDEV inhibitor is particularly selected from sildenafil, Vardenafil, and tadalafil.
- the dose intervals of alpha-2-delta ligand and the PDEV inhibitor correspond to a range of synergistic doses in the order from 1:1 to 10:1 parts by weight, particularly in the range of 1 - 10 mg/kg and 0.1 - 1 mg/kg synergistic doses, respectively, in the rat model of static allodynia induced by CCI .
- Mexican patent application PA/a/2006/003157 aims to the protection of a synergistic combination of an alpha-2-delta ligand and an AChE inhibitor and its use in the curative, prophylactic or palliative treatment of pain, particularly neuropathic pain.
- alpha-2-delta ligands are Gabapentin and pregabalin
- AChE inhibitors are Donepezil, Tacrine, rivastigmine
- compositions comprising a combination of these therapeutic agents.
- US 7713957 B2 patent document refers to a pharmaceutical composition useful for the prevention and/or treatment of neuropathic pain, such as trigeminal neuralgia, post-herpetic neuralgia, or pain caused by infections with HIV, diabetic neuropathy, phantom limb pain, comprising a combination of a) Gabapentin or pregabalin, or pharmaceutically acceptable salts thereof, and b) N-type calcium channel antagonists, or pharmaceutically acceptable salts thereof.
- neuropathic pain such as trigeminal neuralgia, post-herpetic neuralgia, or pain caused by infections with HIV, diabetic neuropathy, phantom limb pain
- WO 2009/046801 Al patent document describes a pharmaceutical composition
- Benfotiamine and one or more pharmaceutically active agents, selected from the group consisting of gabapentin, pregabalin, XP13512, carbamazepine , amitriptyline, ketorolac, diclofenac, ibuprofen, Flurpirtin, Paracetamol, and dexamethasone , process for its preparation and its use for the treatment and prevention of conditions and diseases selected from the group consisting of neuropathic pain conditions.
- pharmaceutically active agents selected from the group consisting of gabapentin, pregabalin, XP13512, carbamazepine , amitriptyline, ketorolac, diclofenac, ibuprofen, Flurpirtin, Paracetamol, and dexamethasone , process for its preparation and its use for the treatment and prevention of conditions and diseases selected from the group consisting of neuropathic pain conditions.
- PA/a/2002 /010764 A patent application aims the protection of an effective combination to relieve pain comprising an effective amount of Endothelin receptor antagonist and 1 to 3 compounds selected from the group consisting of ant iepileptic compounds that have properties to relieve pain such as pregabalin, and analgesics such as Meloxicam as an NSAID, and pharmaceutically acceptable salts thereof; and pharmaceutical compositions comprising them.
- a patent application provides a pharmaceutical composition for treating pain and conditions related to pain, using the administration of a therapeutically effective amount of slow-release Tapentadol hydrochloride and a therapeutically effective amount of a second analgesic to a patient in need thereof, , where the second analgesic is Tramadol, a gamma-aminobutyric acid (GABA) analogue further comprising a NSAID such as Meloxicam.
- GABA gamma-aminobutyric acid
- present MX/a/2007 /014422 patent application refers to synergistic combinations of non-steroidal anti-inflammatory drugs, particularly Carprofen, with alpha-2-delta ligands, such as Gabapentin or pregabalin, for veterinary treatment of pain or inflammation, especially in dogs, cats and horses.
- non-steroidal anti-inflammatory drugs particularly Carprofen
- alpha-2-delta ligands such as Gabapentin or pregabalin
- MX 2011014042 patent document describes pharmaceutical combinations of two antiepilept ic drugs, such as Oxcarbazepine, pregabalin and combinations of an antiepileptic, pregabalin or Oxcarbazepine with B-complex vitamins, as well as pharmaceutical compositions comprising such combinations, and their use for treatment of neuropathic pain .
- two antiepilept ic drugs such as Oxcarbazepine, pregabalin and combinations of an antiepileptic, pregabalin or Oxcarbazepine with B-complex vitamins
- the present invention comprises the synergistic combination of pregabalin and Meloxicam, using lower doses of these active principles than those commonly prescribed when they are administered separately .
- the present invention discloses a novel combination of pregabalin, an ⁇ -aminobutyric acid ⁇ GABA) analogue agent and Meloxicam, a non-steroidal anti ⁇ inflammatory agent (NSAID) , which exhibits a surprising synergistic effect, useful for the prevention and/or treatment of pain caused by different neuropathic etiologies.
- NSAID non-steroidal anti ⁇ inflammatory agent
- the present invention is also aimed at pharmaceutical compositions comprising such synergistic combination, as well as pharmaceutically acceptable excipients or vehicles, formulated to be administered in a single dosage unit, and their use to treat and/or prevent neuropathic pain caused by diabetic neuropathy, neuropathy after herpes zoster appearance, trigeminal nerve neuralgia, HIV, pain of the phantom member after an amputation, neuropathic pain of lumbar and dorsal region.
- the combination and pharmaceutical compositions subject of present invention provide the following not obvious or apparent significant benefits: a) synergic effective interaction between pregabalin and Meloxicam for the prevention and/or treatment of neuropathic pain caused by several etiologies, b) decrease of administered doses of these drugs, particularly those corresponding to the antihyperalgesic, antiallodynic agent compared to the recommended doses of each drug separately, c) administration of a single daily dose, d) better efficacy of the therapeutic synergistic effect which remains throughout the day, e) improved safety profile that allows its administration for prolonged periods, f) minor side effects with respect to those induced with single drug administration.
- FIG. 1 Time courses of pregabalin antiallodynic effect (Pgb) in acetone test (cold allodynia) .
- FIG. 7 Bar graph of global antiallodynic effect for 180 min of pregabalin in rats with chronic constriction injury (CCI) in acetone test (cold allodynia) .
- CCI chronic constriction injury
- acetone test cold allodynia
- Figure 17 Time courses of the antihyperalgesic effect of a combination of Meloxicam + pregabalin in acute treatment, with Von Frey test in rats with chronic constriction injury (CCI) .
- the combination Mel 0.1 mg/kg + Pgb 0.3 mg/kg produced slightly better antihyperalgesic effects than those generated by Pgb 0.3 mg/kg alone.
- Figure 18 Bars representing hyperalgesia degree after each treatment (AUC of corresponding CT) that generated the drugs alone and combined at the ratio used in acute treatment in rats with neuropathic pain.
- Figure 19 Time courses of ant ihyperalgesic effect of a combination of Meloxicam 0.3 + 0.3 pregabalin in acute treatment, with Von Frey test in rats with chronic constriction injury (CCI) .
- the combination Mel 0.3 mg/kg + Pgb 0.3 mg/kg generated best antihyperalgesic effects than those generated by Meloxicam or Pgb alone.
- Figure 20 Bars representing the degree of hyperalgesia which remains after treatment (AUC of corresponding CT) with drugs alone and combined at the ratio employed in acute treatment in rats with neuropathic pain.
- Figure 21 Time courses of the antihyperalgesic effect of a combination of Meloxicam + pregabalin in acute treatment, with Von Frey test in rats with chronic constriction injury (CCI) .
- the combination Mel 1.0 mg/kg + Pgb 0.3 mg/kg showed no better effects than Pgb 0.3 alone.
- Figure 22 Bars representing antihyperalgesic overall effects (AUC of corresponding CT) generated by drugs alone and combined at the ratio employed in acute treatment in rats with neuropathic pain.
- Figure 23 Time courses of the antihyperalgesic effect of a combination of Meloxicam 3.2 + pregabalin 0.3 in acute treatment, with Von Frey test in rats with chronic constriction injury (CCI) .
- Figure 24 Bars representing the overall antihyperalgesic effects (AUC of corresponding CT) generated by drugs alone and combined at the ratio employed in acute treatment in rats with neuropathic pain.
- Figure 26 Bars representing the overall ant ial lodynic effects generated by compounds administered alone and in combination, in acute treatment in rats with neuropathic pain .
- Figure 28 Bars representing the overall ant ial lodynic effects generated by compounds administered alone and in combination, in acute treatment in rats with neuropathic pain .
- Figure 30 Bars representing the antiallodynic overall effects generated by compounds administered alone and in combination, in acute treatment in rats with neuropathic pain .
- Figure 32 Bars representing the overall ant ial lodynic effects generated by compounds administered alone and in combination, in acute treatment in rats with neuropathic pain .
- Figure 33 Time courses of the antihyperalgesic effect of a combination of Meloxicam 0.1 mg/kg + pregabalin 0.3 mg/kg in chronic treatment (2 administrations/day/7 days), with Von Frey test in rats with chronic constriction injury
- Figure 34 Bars representing overall ant ihyperalges ic effects generated by the combination, and comparison with the effects generated by single compounds, for chronic treatment in rats with neuropathic pain.
- Figure 35 Time courses of the antihyperalgesic effect of a combination of Meloxicam 0.3 mg/kg + pregabalin 0.3 mg/kg in chronic treatment (2 administrations/day/7 days) in rats with chronic constriction injury (CCI) .
- Figure 36 Bars representing the global ant ihyperalgesic effects generated by the combination, and global effects produced by individual agents for chronic treatment in rats with neuropathic pain.
- Figure 37 Time courses of the antihyperalgesic effect of a combination of Meloxicam 1.0 mg/kg + pregabalin 0.3 mg/kg in chronic treatment (2 administrations/day/7 days) in rats with chronic constriction injury (CCI) .
- Figure 38 Bars that have global ant ihyperalgesic effects generated by the combination, and the global effects of the individual agents for chronic treatment in rats with neuropathic pain.
- Figure 39 Time courses of the antihyperalgesic effect of a combination of Meloxicam 3.2 mg/kg + pregabalin 0.3 mg/kg in chronic treatment (2 administrations/day/7 days) in rats with chronic constriction injury (CCI) .
- Figure 40 Bars showing global antihyperalgesic effects generated by the combination, and the global effects of individual agents for chronic treatment in rats with neuropathic pain.
- Figure 42 Bars representing the overall ant ial lodynic effects generated by compounds administered alone and in combination, in chronic treatment (14 administrations) in rats with neuropathic pain.
- Figure 44 Bars representing the overall ant ial lodynic effects generated by compounds administered alone and in combination, for chronic treatment in rats with neuropathic pain.
- Figure 46 Bars representing the overall ant ial lodynic effects generated by compounds administered alone and in combination, for chronic treatment in rats with neuropathic pain .
- Figure 48 Bars representing the overall ant ial lodynic effects generated by compounds administered alone and in combination, for chronic treatment in rats with neuropathic pain .
- Figure 49 DRC of antihyperalgesic effects of Mel alone and Mel + Pgb 0.3 in acute treatment. Improvement of effects is apparent when Mel small doses are associated with Pgb, giving evidence of interaction of effect enhancement in treatment of hyperalgesia in neuropathic pain.
- Figure 50 DRC of antlallodynic effects of Mel alone and Mel + 0.3 Pgb. Improvement effects of small doses of Mel when associated with 0.3 Pgb in treatment of allodynia in neuropathic pain is detected.
- Figure 51 DRC of antihyperalgesic effects of Mel alone and Mel + Pgb 0.3 in chronic treatment. There is an effect improvement when Mel is associated with Pgb, giving evidence of interaction in the treatment of hyperalgesia in neuropathic pain.
- Figure 52 DRC of antlallodynic effects of Mel alone and Mel + Pgb 0.3 in chronic administration. Improving antlallodynic effects of small doses of Mel are showed when associated with 0.3 Pgb, in treatment of neuropathic pain.
- Figure 53 Bars showing global ant lallodynic effects generated by Mel 0.1 and 0.3 Pgb and change effect when Mel 0.1 is combined with 0.3 Pgb in chronic treatment; and comparison of these effects from the combination with those generated by Mel 10 mg/kg alone chronic, in rats with neuropathic pain.
- the present invention refers to a pharmaceutical combination of a ⁇ -aminobutyric acid (GABA) analogue antihyperalgesic, antiallodynic agent, and a non-steroidal type anti-inflammatory agent, (NSAID) , which showed a surprising synergistic effect, and pharmaceutical compositions comprising such a combination as well as pharmaceutically acceptable excipients or vehicles.
- GABA ⁇ -aminobutyric acid
- NSAID non-steroidal type anti-inflammatory agent
- a preferred embodiment of the present invention relates to a pharmaceutical combination comprising pregabalin or a pharmaceutically acceptable thereof, and Meloxicam or a pharmaceutically acceptable salt thereof, which showed an effective synergistic effect; and pharmaceutical compositions comprising such a combination as well as pharmaceutically acceptable excipients or vehicles, formulated to be administered by oral or parenteral route in a single dosage unit.
- Both the combination and the pharmaceutical compositions of the present invention proved to be effective in the prevention and/or treatment of neuropathic pain caused by several etiologies, such as diabetic neuropathy, neuropathy after herpes zoster appearance, trigeminal nerve neuralgia, HIV, pain of the phantom member after an amputation, neuropathic pain of lumbar and dorsal region.
- neuropathic pain caused by several etiologies, such as diabetic neuropathy, neuropathy after herpes zoster appearance, trigeminal nerve neuralgia, HIV, pain of the phantom member after an amputation, neuropathic pain of lumbar and dorsal region.
- a neuropathic pain CCI model was firstly standardized. Rats were anesthetized and the dissection of the sciatic nerve of the right thigh by an incision was immediately performed, dissecting the muscle biceps femoris to locate the most proximal part to the trifurcation of the sciatic nerve and applying four loose ties with silk thread. At the end of the surgery, muscle was sutured with absorbable thread and skin with silk thread. Falsely operated rat (Sham) surgery was performed in the same way but without linking the sciatic nerve .
- the degree of hyperalgesia and allodynia in rats subject to sciatic nerve surgery was determined using Von Frey test and the acetone test. These determinations were made a day before the surgery, and a time course of 180 minutes 7 days after surgery was performed for both control (saline) and for orally administered compounds in the study, both alone and combined, to reveal hyperalgesia and allodynia that were present. Then a hyperalgesia and allodynia time course, but now in rats with chronic treatment (1 Administration every 12 hours) making determinations of hyperalgesia and allodynia 30 minutes after administration of treatment in study conducted in the morning and in the following period: 0, 1, 3, 5 and 7 days (in total 14 administrations) . Von Frey Test (mechanical hyperalgesia) .
- Rats were placed on a metal mesh in an acrylic box transparent where they remained at least 10 minutes before the test for adaptation.
- controls Sham and non-surgical
- presented some nociceptive response therefore, in this case the response is deemed of hyperalgesia.
- Acetone test (cold allodynia) .
- neuropathic pain sciatic nerve ligation
- sciatic nerve ligation Different groups of animals with neuropathic pain (sciatic nerve ligation) were established, each group consisting of 6 animals. Effects of mechanical hyperalgesia were evaluated on these animals (Von Frey 15 g filaments) and cold allodynia (acetone test), both as reflection of the degree of neuropathic pain affecting the animals, before and after acute and chronic treatments.
- a CCI animal control group was established followed by 31 days in order to observe the time course of hyperalgesia and allodynia development, and to determine the permanence in time of hyperalgesia and allodynia.
- a SHAM control group was established having only a dissection without performing surgery or ligation of sciatic nerve, to demonstrate that neuropathic pain alone is present if done right on the sciatic nerve ligation.
- CCI-VEH that does have sciatic nerve surgery or ligation, but not drug treatment was established.
- DRC dose-response curve
- Figure 1 shows the effects determined in control groups, where the response of hyperalgesia is apparent (response close to 100% in rats who have surgery (CCI-VEH ⁇ , ⁇ "), and there is evidence of a lack of vehicle antihyperalgesic effect.) While the rats which were not linked (SHAM '®') show a small nociceptive response to stimulation with 15 g filament, the response is very close to zero, but they actually show some degree of response, which shows that there is whether pain or nociception with a 15 g Von Frey filament, and that rats present hyperalgesia after CCI surgery. Mean ⁇ standard error is plotted.
- Fig. 2 shows the CT of antihyperalgesic effects generated by each of pregabalin evaluated doses (PGB or Pgb) in rats with neuropathic pain. The response percentage generated by different doses is evaluated.
- the X axis shows the time in minutes with determinations in time 0, 30, 60, 90, 120 and 180 minutes after oral administration of each dose.
- Y axis shows that animals had virtually 100% of hyperalgesia response at beginning, but after administration of each dose, hyperalgesia decreased in a dose-dependent manner. Mean and standard error are plotted for 6 animals in each point.
- An antihyperalgesic effect generated by Pgb is apparent as the dose increases. Also observed that while the Pgb 0.1 mg/kg ($) dose virtually generates no antihyperalgesic effects, the 10 mg/kg (II) dose produces maximum antihyperalgesic effect.
- Figure 3 presents the global antihyperalgesic effects, through 180 minutes in the form of bars corresponding to the area under the curve (AUC) of the antihyperalgesic effects shown in the CT above.
- Figure 4 shows the DRC of antihyperalgesic effects developed by oral pregabalin in rats with neuropathic pain caused by chronic constriction injury using Von Frey ( 15 g filament) test. Being the time course of 3 h, a maximum control area under the curve (AUC) was established as a value of 300 units of area (ua) . With this value, the corresponding values of ant ihyperalgesic effects were calculated.
- AUC control area under the curve
- Figure 5 shows the effects determined in control groups, wherein the allodynic response is apparent (response close to 2 5 seconds) in rats who have surgery (CCI-VEH " "), and there is evidence of a lack of antiallodynic effect of vehicle. While rats which were not linked (SHAM) showed no nociceptive response (limb removal in seconds) upon being stimulated with acetone (data not shown) . Mean ⁇ standard error is plotted.
- Figure 6 shows the CT found with each individual dose of Pgb.
- the "X" axis shows times where antiallodynic effect generated by PGB in each dose was assessed, while Y axis shows the allodynia developed in animals, expressed in accumulated seconds of limb removal. Mean ⁇ standard error is plotted. 10 mg/kg is seen as the most effective dose.
- Figure 7 presents more clearly the dose-dependent relationship of pregabalin ant iallodynic effect by calculating AUC of CT shown in Figure 6.
- Figure 8 shows the DRC of the antiallodynic effects which developed oral pregabalin in rats with neuropathic pain caused by chronic constriction injury using acetone test to produce cold allodynia. Being 3 h the time course, a value of 90 ua was established as control maximum area under the curve (AUC) . With this value, the corresponding values of antiallodynic effects were calculated.
- Figure 9 shows the CT of ant ihyperalgesic effects generated by Meloxicam (Melox or Mel) evaluated in rats with neuropathic pain.
- "X” axis shows the time in minutes with determinations in time 0, 30, 60, 90, 120 and 180 minutes after oral administration of each dose.
- "Y” axis shows that animals had hyperalgesia after stimulation with Von Frey filaments, but after Meloxicam administration hyperalgesia was decreasing. Mean and standard error of at least 6 animals in each point are plotted.
- Figure 10 presents antihyperalgesic global effects through 180 minutes in the form of bars corresponding to the area under the curve (AUC) of antihyperalgesic effects shown in above CT .
- Figure 11 shows a DRC of antihyperalgesic effects developed by oral Meloxicam in rats with neuropathic pain caused by chronic constriction injury using Von Frey (15 g filament) test.
- AUC maximum control possible area under the curve
- Figure 12 shows the CT found with each individual Meloxicam dose.
- the "X” axis shows times in which the antiallodynic effect generated by Melox in each dose was evaluated, while "Y” shows allodynia developed in animals, expressed in accumulated seconds from limb removal. Mean ⁇ standard error is plotted. 31.6 mg/kg is seen as the most effective dose.
- Figure 14 shows a DRC of the antiallodynic effects developed by oral Meloxicam in rats with neuropathic pain caused by chronic constriction injury using acetone test to produce cold allodynia. Being the time course of 3 h, a value of 90 ua was determined as the maximum possible control area under the curve (AUC) , and with this value the corresponding values of antiallodynic effects were calculated.
- AUC maximum possible control area under the curve
- Pregabalin DRC more in left side on "X" axis
- pregabalin proved to be more powerful than Meloxicam, both for ant ihyperalgesic and ant iallodynic effects, accurately calculating potency using their respective ED 50 :
- -In antihyperalgesic effects Pregabalin was 4.3 times more potent than Meloxicam, even though both exhibited similar antihyperalgesic efficacy.
- Pregabalin was 7.0 times more potent than Meloxicam, although both exhibited similar ant iallodynic efficacy.
- ANTINOCICEPTIVE EFFICACY (ANTIHYPERALGESIA AND ANTIALLODYNIA) IN NEUROPATHIC PAIN, MELOXICAM AND PREGABALIN IN COMBINATION.
- Meloxicam 7.5 to 15 mg with pregabalin 75 to 150 mg, orally administered Compounds in the following dosages used in clinical practice were assessed: Meloxicam 7.5 to 15 mg with pregabalin 75 to 150 mg, orally administered. But in preclinical practice as noticed from previously presented DRC in rat, active or effective Meloxicam dose ranges from 1.0 to 31.6 mg/kg orally, while in the case of oral pregabalin dose in rat ranges from 0.1 to 10 mg/kg.
- Figure 18 presents a bar chart to show with areas under the curve (AUC) of the corresponding time courses, coverage through time of antihyperalgesic effects.
- AUC areas under the curve
- "X" axis shows administered treatment
- "Y” axis shows the degree of hyperalgesia as AUC demonstrated after the treatment.
- a large AUC should remind that high hyperalgesia and low antihyperalgesic effect are present, while a small AUC points out that there is little hyperalgesia, therefore, a great antihyperalgesic effect after treatment.
- Figure 19 shows time courses (CT) obtained in neuropathic rats administered with another different combination ratio of Meloxicam 0.3 mg/kg + pregabalin 0.3 mg/kg.
- CT time courses
- axis "X” shows time (min) used to determine the time course of acute effects for 180 minutes from administrations
- "Y” axis shows antihyperalgesic effects (%) generated by each drug alone or in combination.
- Mean ⁇ standard error of n 6 rats with neuropathic pain were plotted.
- Figure 20 presents a bar graph to demonstrate antihyperalgesic effects with areas under the curve (AUC) of corresponding time courses. Results from this combination ratio show that animals receiving Mel 0.3 have still high hyperalgesia, while groups of rats receiving the combination Mel 0.3 + Pgb 0.3 mg/kg showed less hyperalgesia; therefore, more antihyperalgesic effects with treatment in acute form.
- Figure 21 shows time courses (CT) obtained by administering another different combination ratio: Meloxicam 1.0 mg/kg + pregabalin 0.3 mg/kg. It should be noticed that Meloxicam in a 1.0 mg/kg (.4) dose begins to generate antihyperalgesic effects along the evaluated time course. Pgb 0.3 mg/kg (#) generates a small antihyperalgesic effect, as the combination Mel 1.0 + Pgb 0.3 mg/kg (H) . Even though a combination of figures 19 and 20 used less Meloxicam (0.3 mg/kg) , generated a better interaction than when Meloxicam dose is up to 1 mg/kg.
- Figure 22 shows the bar graph to demonstrate antihyperalgesic effects with areas under the curve (AUC) of corresponding time courses. Results with this combination ratio show that animals receiving the combination showed better effects than Meloxicam alone, but very similar to those showed by Pgb alone.
- Figure 23 shows time courses (CT) obtained by administering another different combination ratio: Meloxicam 3.2 mg/kg + pregabalin 0.3 mg/kg.
- Meloxicam in 3.2 mg/kg (.4) doses generates poor antihyperalgesic effects over the evaluated time course.
- Pgb 0.3 mg/kg ( ⁇ ) generates a small ant ihyperalgesic effect
- Figure 24 shows a bar chart showing with areas under the curve (AUC) , the corresponding time courses of antihyperalgesic effects. Results with this combination ratio showed that animals receiving Mel 3.2 expressed little antihyperalgesic effects. The group receiving the combination Mel 3.2 + 0.3 Pgb showed similar antihyperalgesic effects than those produced by 0.3 pregabalin in acute administration . Analysis of antiallodynic effects of compounds alone and in combination in acute administration.
- Figure 26 and following bar charts showed in "X" axis the administered treatment and in "Y" axis allodynia (AUC of time course) . Given that the larger AUC, the higher allodynia effect and the lower antiallodynic effect is, the effects of Meloxicam 0.1 and 0.3 Pgb are noticed in the figure to be very similar, but the combination showed higher antiallodynic effects .
- Figure 27 shows the results found in terms of antiallodynic effects of a combination Mel 0.3 + Pgb 0.3 mg/kg. Although CTs are very similar, a slight better effect with the combination is present.
- Figure 28 shows AUC bars from allodynia in rats treated with compounds alone and combined. A better antiallodynic effect is clearer with a combination Mel 0.3 + Pgb 0.3 mg/kg than with individual compounds .
- Figure 29 shows the results found in terms of ant iallodynic effects of the combination Mel 1.0 + Pgb 0.3 mg/kg.
- the CT show that while Mel 1.0 mg/kg did not generate adequate ant iallodynic effects, Pgb 0.3 mg/kg had slightly better effects, and that the corresponding combination also produced a slight better time course.
- Figure 30 shows AUC bars from allodynia in rats treated with compounds alone and combined: Mel 1.0 + Pgb 0.3 mg/kg. Ant iallodynic effect is better with the combination than with individual compounds which evidence a slight ant iallodynic effect .
- Figure 31 shows the results found in terms of ant iallodynic effects of a combination Mel 3.2 + Pgb 0.3 mg/kg.
- the CT showed that ant iallodynic effect of Mel alone and Pgb alone is very similar, but the combination generates better ant iallodynic effects.
- Figure 32 shows AUC bars from allodynia in rats treated with compounds alone and combined: Mel 3.2 + Pgb 0.3 mg/kg. There is clearly a better effect with the combination.
- Figure 34 shows in a bar graph the overall antihyperalgesic effects generated by individual compounds and in combination.
- the antihyperalgesic effect of the combination in chronic administration is lower than the effect generated by Pgb alone.
- Figure 36 bar graph shows antihyperalgesic global effects generated by individual compounds and in combination.
- Antihyperalgesic effect of the combination and Pgb 0.3 alone is similar in chronic administration, and better than those produced by Meloxicam 0.3 mg/kg alone.
- Figure 37 shows that combining Meloxicam 1.0 + pregabalin 0.3 (*) mg/kg produces very similar effects to Pgb
- Figure 38 bar graph shows overall antihyperalgesic effects generated by individual compounds and in combination Mel 1.0 + 0.3 Pgb. Chronic administration is similar to the ant ihyperalgesic effect of the combination and Pgb 0.3 and better than Meloxicam 1 mg/kg.
- Figure 39 shows that combination Meloxicam 3.2 + 0.3 pregabalin mg/kg produced only a trend of better ant ihyperalgesic effects than produced by Pgb 0.3 (A) .
- Figure 40 bar graph shows global ant ihyperalgesic effects generated by individual compounds and combination Mel 3.2 + 0.3 Pgb. In chronic administration, ant ihyperalgesic effect of the combination and Pgb 0.3 alone is similar.
- Figure 42 and following bar figures showed the administered treatment in "X" axis and allodynia still present after administrations (AUC of corresponding time course) in "Y" axis. Since the larger is AUC the higher allodynia effect and the lower the antlallodynic effect is, the figure shows that ant ial lodynic effects of the combination were higher than those produced by Mel 0.1 or Pgb 0.3 mg/kg .
- Figure 43 shows the results found in terms of antlallodynic effects of a combination Mel 0.3 + Pgb 0.3 mg/kg.
- the combination shows better and higher ant lallodynic effects than Mel 0.3 or Pgb 0.3 mg/kg alone.
- Figure 44 shows that Pgb 0.3 shows poor ant lallodynic effects, Mel 0.3 showed higher antlallodynic effects to Pgb, but the combination Mel 0.3 + 0.3 Pgb generated better antlallodynic effects.
- Figure 48 evidences in bar charts with the corresponding area under the curve that antiallodynic effects of a combination Mel 3.2 + Pgb 0.3 mg/kg in chronic treatment are better than compounds administered on an individual basis.
- Figure 49 shows the DRC of antihyperalgesic effects of Mel alone and DRC of Mel associated to Pgb 0.3 mg/kg acute treatment, and also the timely effect of Pgb 0.3 mg/kg is shown for the purpose of comparison.
- the DRC obtained with "Meloxicam alone” has the shape of the perfect sigmoid described for drugs in the classical pharmacological literature.
- the DRC of Meloxicam in small doses administered simultaneously with pregabalin 0.3 mg/kg has an irregular shape and does not correspond to a classic sigmoid. But this is "normal” or usual when drugs are administered simultaneously and interaction effects are observed, where a dose-dependent relation for enhancement or addition effects is not followed. That is, when drug interaction occurs, this interaction does not increase as interaction doses are increased, having some combination ratios that can generate enhancement, while increasing or decreasing said drug doses in combination can only provide a sum effect or even in some cases, infra-additive effects or antagonism type can be generated.
- DRC may appear "irregular" where a dose in combination can produce enhancement, while a combination of lower or higher doses can produce much minor or no interaction effects. This is why DRC occurs irregularly when interacting Meloxicam with Pgb 0.3 mg/kg .
- Meloxicam in doses of 10 mg/kg produced an ant ihyperalgesic effect of 175.0 ⁇ 15.3 ua, and this same effect can be produced using a combination of Mel 0.3 mg/kg + Pgb 0.3 mg/kg producing an effect of 148.3 ⁇ 10.9 ua .
- a traditional analysis of pharmacological potency may be conducted since there is no classic sigmoid given by combinations, allowing determining an ED 50 of the combination.
- a fixed antihyperalgesic pharmacological effect may be defined obtained by Meloxicam alone and combined and thus the relative potency at that particular effect point is determined.
- Meloxicam 10 mg/kg produced the same effect as achieved with Meloxicam 0.3 mg/kg + pregabalin 0.3 mg/kg, so Meloxicam in combination was 33.3 times more potent than when Meloxicam was used alone.
- This data of relative potency should be clarified ass determined at a 160 ua antihyperalgesia fixed effect.
- Another important aspect is the fact that we can detect the importance of combining these drugs after analyzing various combination ratios and detect the range of results that could be generated, since having analyzed only one combination (as in many research articles, but not as proper) , we would not have certainty of having selected the best combination or more correct doses and we could have fallen into an error of concluding that Mel + Pgb the association does not generate antihyperalgesic interaction.
- Figure 50 shows the DRC of antiallodynic effects of "Mel Alone” and found effects by administering "Mel associated with Pgb 0.3 mg/kg", and also shows the specific effect of Pgb 0.3.
- DRC of "Mel Alone” shows the sigmoid feature obtained with 1.0, 3.2, 10.0 and 31.6 mg/kg po doses, reaching its maximum efficacy with a 31.6 mg/kg dose. While administration of the same Mel dose but now together with Pgb at a 0.3 mg/kg dose produced better effects with smaller Meloxicam doses (*) .
- the effect developed by Pgb 0.3 mg/kg (A) alone is also included.
- a chronic treatment may be established with Meloxicam in small doses, as Mel 0.3 mg/kg (see Figure 51) produced as antihyperalgesic effect 173.3 ⁇ 23.1 ua, but this same dose increased its effectiveness when combined with Pgb 0.3 to produce 327.5 35.0 ⁇ ua. Again by moving the DRC of the combination to the left is indicated that antihyperalgesic potency increased with the combination.
- An issue that limits a use evaluation of the combination in these conditions is that Pgb 0.3 mg/kg alone produced an effect of 296.7 ⁇ 27.9 ua .
- CCI neuropathic pain induced by chronic constriction of sciatic nerve in rat
- pregabalin was as effective as Meloxicam.
- pregabalin was as effective as Meloxicam.
- pregabalin was more powerful than
- the present invention also includes the formulation of pharmaceutical compositions comprising a synergistic combination of pregabalin or a pharmaceutically acceptable salt thereof in a therapeutically effective amount, and Meloxicam or a pharmaceutically acceptable salt thereof in a therapeutically effective amount, in addition to one or more pharmaceutically acceptable excipients or vehicles.
- compositions comprising the synergistic pharmaceutical combination of the present invention together with pharmaceutically acceptable excipients or vehicles are formulated to be supplied in a single dosage unit.
- compositions can be formulated to be administered by oral, enteral, parenteral, topical, transdermal, intranasal, ophthalmic route or any other route of administration.
- Suitable routes of administration to the present invention, in a preferred but not restricted manner are oral and parenteral.
- Pharmaceutical forms or appropriate dosage units for the present invention are selected from capsules, tablets, capsules, powders, granulates, lyophilized, drops; injectable solutions, suspensions or emulsions.
- Preferred pharmaceutical forms for present invention are capsules and tablets.
- compositions of the present invention can also be made in release-controlled or modified (prolonged, delayed or slow) pharmaceutical forms.
- compositions or vehicles used in the present invention are selected from the group consisting of binding agents, solubilizers , lubricants, disintegrants , surfactants, granulating agents, dispersants, coating, glidants, non-stick agents, adsorbents, emulsifiers, solvents, thinners, preservatives, flavors, sweeteners, colorants, or any other necessary for the formulation of such pharmaceutical compositions .
- Formulations comprising a pharmaceutical combination of present invention may include exemplarily but not limited to, one or more of the following excipients or vehicles: methylcellulose, carboxymethylcellulose , hydroxypropyl cellulose, ethylcellulose , starches from corn, potato and rice; polyvinylpyrrolidone (PVP), sodium and potassium alginate, propylene glycol (PEG) , gelatin, acacia gum, tragacanth gum, xanthan gum, pectin, xylitol, sorbitol, maltitol; vitamin E polyethylene glycol succinate, sodium lauryl sulfate, pyrrolidone, poloxamer, polysorbate, povidone, derivatives from castor oil, cyclodextrins , hypromellose, lecithin; talc, sodium, magnesium, calcium or zinc stearates, stearic acid, polyethylene glycols, sodium acetate, stearyl fumarate
- the present invention can be also formulated in a case or sectioned packaging adapted to contain the active ingredients in two or more separate dosage units, i.e., drugs can be contained in various dosage forms, thus a first drug can be for example, in a pharmaceutical form in capsules, and the second drug in another different from the first pharmaceutical form, for example in injectable solution.
- used dosage of the active ingredient pregabalin or pharmaceutically acceptable salts thereof ranges within a concentration range from 12.5 mg . to 300 mg, preferably administered therapeutically effective amount of 75 and 150 mg in a single daily dose.
- the Meloxicam active ingredient dosage or pharmaceutically acceptable salts thereof used in the present invention ranges within a concentration range from 5 mg to 20 mg, preferably a therapeutically effective amount of 7.5 and 15 mg in a single daily dose being administered.
- Meloxicam were mixed with polysorbate, mannitol, microcrystalline cellulose, magnesium stearate and colloidal silicon dioxide.
- Meloxicam were mixed with castor oil, mannitol, lactose, stearyl fumarate and colloidal silicon dioxide.
- a combination of 75 mg of pregabalin and 15 mg of Meloxicam were mixed with cyclodextrins , corn starch, lactose, talc and colloidal silicon dioxide.
- a combination of 75 mg of pregabalin and 15 mg of Meloxicam were mixed with poloxamer, mannitol, corn starch, magnesium stearate and colloidal silicon dioxide.
- EXAMPLE 5 A combination of 75 mg of pregabalin and 7.5 mg of Meloxicam were mixed with cyclodextrins , corn starch, lactose, talc and colloidal silicon dioxide.
- Meloxicam were mixed with poloxamer, mannitol, corn starch, magnesium stearate and colloidal silicon dioxide.
- a combination of 75 mg of pregabalin and 7.5 mg of Meloxicam were mixed with polysorbate, mannitol, microcrystalline cellulose, magnesium stearate and colloidal silicon dioxide.
- a combination of 75 mg of pregabalin and 7.5 mg of Meloxicam were mixed with castor oil, mannitol, lactose, stearyl fumarate and colloidal silicon dioxide.
- a combination of 150 mg of pregabalin and 15 mg of Meloxicam were mixed with polysorbate, mannitol, microcrystalline cellulose, magnesium stearate and colloidal silicon dioxide.
- EXAMPLE 10 A combination of 150 mg of pregabalin and 15 mg of Meloxicam were mixed with castor oil, mannitol, lactose, stearyl fumarate and colloidal silicon dioxide.
- Meloxicam were mixed with cyclodextrins , corn starch, lactose, talc and colloidal silicon dioxide.
- a combination of 150 mg of pregabalin and 15 mg of Meloxicam were mixed with poloxamer, mannitol, corn starch, magnesium stearate and colloidal silicon dioxide.
- a combination of 150 mg of pregabalin and 7.5 mg of Meloxicam were mixed with cyclodextrins , corn starch, lactose, talc and colloidal silicon dioxide.
- a combination of 150 mg of pregabalin and 7.5 mg of Meloxicam were mixed with poloxamer, mannitol, corn starch, magnesium stearate and colloidal silicon dioxide.
- a combination of 150 mg of pregabalin and 7.5 mg of Meloxicam were mixed with castor oil, mannitol, lactose, stearyl fumarate and colloidal silicon dioxide.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112017000359-7A BR112017000359A2 (en) | 2014-07-07 | 2015-07-07 | Pregabalin and Meloxicam combination for the treatment of neuropathic pain |
CONC2017/0001076A CO2017001076A2 (en) | 2014-07-07 | 2017-02-06 | Antihyperalgesic, anti-allodinic and anti-inflammatory pharmaceutical compositions containing pregabalin and meloxicam |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2014008336A MX2014008336A (en) | 2014-07-07 | 2014-07-07 | Antihyperalgesic, antiallodynic and anti-inflammatory pharmacological combination, pharmaceutical compositions containing same and use thereof for treating neuropatic pain. |
MXMX/A/2014/008336 | 2014-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016005897A1 true WO2016005897A1 (en) | 2016-01-14 |
Family
ID=53938368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/055127 WO2016005897A1 (en) | 2014-07-07 | 2015-07-07 | Combination of pregabalin and meloxicam for the treatment of neuropathic pain |
Country Status (5)
Country | Link |
---|---|
BR (1) | BR112017000359A2 (en) |
CO (1) | CO2017001076A2 (en) |
MX (1) | MX2014008336A (en) |
PE (1) | PE20171140A1 (en) |
WO (1) | WO2016005897A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3687520A4 (en) * | 2017-09-28 | 2021-06-23 | Nevakar, Inc | Fixed dose combination formulations for treating pain |
EP4000607A4 (en) * | 2019-07-16 | 2022-09-14 | Amézcua Amézcua, Federico | Synergistic combination of s-ketorolac and pregabalin in a pharmaceutical composition for the treatment of neuropathic pain |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112353767A (en) * | 2020-11-16 | 2021-02-12 | 海南锦瑞制药有限公司 | Diltiazem hydrochloride and pregabalin composition, and preparation method and application thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02001076A (en) | 1999-08-04 | 2002-08-20 | Colgate Palmolive Co | Stable hydrogenated lupulone antibacterial oral compositions. |
MXPA06000315A (en) | 2003-07-10 | 2006-03-30 | Siemens Ag | Communication system, computer comprising a peer-to-peer message filter and method for processing a peer-to-peer message. |
MX2007014422A (en) | 2005-05-20 | 2008-02-11 | Pfizer Ltd | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands. |
WO2009046801A1 (en) | 2007-10-09 | 2009-04-16 | Merck Patent Gmbh | Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin |
US7713957B2 (en) | 2002-02-05 | 2010-05-11 | Ajinomoto Co., Inc. | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist |
MX2010005680A (en) | 2007-11-23 | 2010-12-21 | Protect Pharmaceutical Corp | Tapentadol compositions. |
MX2011014042A (en) | 2011-12-16 | 2013-06-17 | Senosiain S A De C V Lab | Antineuritic pharmaceutical combination and compositions. |
-
2014
- 2014-07-07 MX MX2014008336A patent/MX2014008336A/en unknown
-
2015
- 2015-07-07 WO PCT/IB2015/055127 patent/WO2016005897A1/en active Application Filing
- 2015-07-07 PE PE2017000033A patent/PE20171140A1/en unknown
- 2015-07-07 BR BR112017000359-7A patent/BR112017000359A2/en not_active Application Discontinuation
-
2017
- 2017-02-06 CO CONC2017/0001076A patent/CO2017001076A2/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02001076A (en) | 1999-08-04 | 2002-08-20 | Colgate Palmolive Co | Stable hydrogenated lupulone antibacterial oral compositions. |
US7713957B2 (en) | 2002-02-05 | 2010-05-11 | Ajinomoto Co., Inc. | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist |
MXPA06000315A (en) | 2003-07-10 | 2006-03-30 | Siemens Ag | Communication system, computer comprising a peer-to-peer message filter and method for processing a peer-to-peer message. |
MX2007014422A (en) | 2005-05-20 | 2008-02-11 | Pfizer Ltd | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands. |
WO2009046801A1 (en) | 2007-10-09 | 2009-04-16 | Merck Patent Gmbh | Pharmaceutical compositions containing benfotiamine and one or one more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin |
MX2010005680A (en) | 2007-11-23 | 2010-12-21 | Protect Pharmaceutical Corp | Tapentadol compositions. |
MX2011014042A (en) | 2011-12-16 | 2013-06-17 | Senosiain S A De C V Lab | Antineuritic pharmaceutical combination and compositions. |
Non-Patent Citations (7)
Title |
---|
EMILIO BLANCO TARRIO ET AL: "Effectiveness of Pregabalin as Monotherapy or Combination Therapy for Neuropathic Pain in Patients Unresponsive to Previous Treatments in a Spanish Primary Care Setting", CLINICAL DRUG INVESTIGATION, vol. 33, no. 9, 3 August 2013 (2013-08-03), pages 633 - 645, XP055214489, ISSN: 1173-2563, DOI: 10.1007/s40261-013-0116-7 * |
J CARLO LUCA ROMANO; DELIA ROMANO; CRISTINA BONORA; GIUSEPPE MINEO: "Celecoxib, Pregabalin, and their combination for treatment of chronic low-back pain", J ORTHOPAED TRAUMATOL, vol. 10, 2009, pages 185 - 191, XP019743999, DOI: doi:10.1007/s10195-009-0077-z |
JOHANN F. COETZEE; RUBY A. MOSHER; LAURA E. KOHAKE; CHARLEY A. CULL; LINDSEY L. KELLY; STACY L. MUETING; BUTCH KUKANICH: "Pharmacokinetics of oral Gabapentin alone or co-administered with Meloxicam in ruminant beef calves", THE VETERINARY JOURNAL, vol. 190, 2011, pages 98 - 102, XP028307771, DOI: doi:10.1016/j.tvjl.2010.08.008 |
R. JOKELA; J. AHONEN; M. TALLGREN; M. HAANPAA; K. KORTTILA: "Premedication with Pregabalin 75 or 150 mg with Ibuprofen to control pain after day-case gynaecological laparoscopic surgery", BRITISH JOURNAL OF ANAESTHESIA, vol. 100, no. 6, 2008, pages 834 - 40 |
ROBERT W. HURLEY; MD., PHD.; DEBIKA CHATTERJEA, B.S.; MEIHUA ROSE FENG, PH.D.; CHARLES P. TAYLOR, PH.D.; DONNA L.; HAMMOND, PH.D.: "Gabapentin and Pregabalin can interact synergistically with Naproxen to produce antihyperalgesia", ANESTHESIOLOGY, vol. 97, 2002, pages 1263 - 73 |
SEIJI OHTORI ET AL: "Efficacy of Combination of Meloxicam and Pregabalin for Pain in Knee Osteoarthritis", YONSEI MEDICAL JOURNAL, vol. 54, no. 5, 1 January 2013 (2013-01-01), pages 1253, XP055214507, ISSN: 0513-5796, DOI: 10.3349/ymj.2013.54.5.1253 * |
SHIMIZU KAZUTAKA ET AL: "Evaluation of Pregabalin Therapy in Peripheral Neuropathy", IMMUNOLOGY ENDOCRINE & METABOLIC AGENTS IN MEDICINAL CHEMISTRY, vol. 13, no. 2, June 2013 (2013-06-01), pages 132 - 138, XP002744801 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3687520A4 (en) * | 2017-09-28 | 2021-06-23 | Nevakar, Inc | Fixed dose combination formulations for treating pain |
US11590094B2 (en) | 2017-09-28 | 2023-02-28 | Nevakar Injectables Inc. | Fixed dose combination formulations for treating pain |
EP4000607A4 (en) * | 2019-07-16 | 2022-09-14 | Amézcua Amézcua, Federico | Synergistic combination of s-ketorolac and pregabalin in a pharmaceutical composition for the treatment of neuropathic pain |
Also Published As
Publication number | Publication date |
---|---|
PE20171140A1 (en) | 2017-08-09 |
BR112017000359A2 (en) | 2018-06-26 |
MX2014008336A (en) | 2016-01-07 |
CO2017001076A2 (en) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5241228B2 (en) | Multi-layered tablets containing non-steroidal anti-inflammatory drugs, decongestants and less sedating antihistamines | |
US6936601B2 (en) | Compositions for treating pain | |
DK167996B1 (en) | PAIN-COMBINING PREPARATION CONTAINING A CAPSAIC COMPOUND AND NON-STEROID ANTI-INFLAMMATORY COMPOUND | |
JP2018048189A (en) | Drug combinations and uses in treating a coughing condition | |
US20230414572A1 (en) | Prevention or treatment of sleep disorders using dexmedetomidine formulation | |
CN105534921A (en) | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders | |
JPH0733331B2 (en) | Analgesic and anti-inflammatory compositions comprising diphenhydramines | |
RU2670272C2 (en) | Oral pharmaceutical composition suitable for improving effectiveness of treatment of motor disorders | |
TW201136916A (en) | New uses | |
CA3213864A1 (en) | Dosing regimen of tradipitant | |
AU703242B2 (en) | Film coated tablet of paracetamol and domperidone | |
AU2005223655B2 (en) | Methods for treating alcoholism | |
US20210353559A1 (en) | Composition and method for treating neurological disease | |
US11744833B2 (en) | Pharmaceutical compositions and methods for treatment of insomnia | |
WO2016005897A1 (en) | Combination of pregabalin and meloxicam for the treatment of neuropathic pain | |
RU2261098C2 (en) | Mirtazapine-containing orally decomposing composition | |
WO2007069925A2 (en) | Non-neurotoxic recreational drugs and a method of treating recreational drug abuse | |
NO309965B1 (en) | Oral pharmaceutical anti-cough preparation | |
RU2461374C1 (en) | Biologially active agent having effect on general metabolic, excitatory and inhibitory nerve function and intellectual mnestic cerebral functions (versions) | |
RU2464013C1 (en) | Combination in oral dispersible form with therapeutic action on activating and inhibitory functions of nervous system (versions) | |
BRPI0908988A2 (en) | oral galenic formulation including ketorolac and B vitamins, in which vitamin B6 is in an outer layer separate from the rest of the active ingredients | |
US6511982B2 (en) | Treatment of pain | |
WO2023158424A1 (en) | Novel pharmaceutical compositions and methods for treatment of insomnia | |
US9155704B1 (en) | More palatable, bioequivalent pharmaceutical composition of carprofen | |
JP2020525548A (en) | Peripherally localized dual-acting kappa and delta opioid agonists for analgesia in painful conditions with inflammatory response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15753769 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000033-2017 Country of ref document: PE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: NC2017/0001076 Country of ref document: CO |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15753769 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017000359 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112017000359 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170106 |